IPO
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industry is still booming coming out of the COVID-19 pandemic.
The 2021 IPO stampede continues with five more companies aiming to trade on a stock exchange.
Tossing their names in the hat just before long weekend, four life sciences companies filed for $100 million IPOs Friday afternoon.
The first half of 2021 has seen a flurry of IPOs as companies make the move to become publicly traded. The trend continued, as biopharma companies hit the stock exchange this week.
Cambridge, Mass.-based Intellia Therapeutics has had a busy week, but they’re topping it off with the announcement of their public offering price of $145 per share for 4,137,931 shares.
Multiple pharma company stocks make their first appearance on the Nasdaq this morning to advance the next-generation therapeutics. BioSpace takes a look at some of these IPOs.
Biotech companies are dominating Nasdaq’s IPO scheduled this week. Here’s who is making their big public debut.
Umoja Biopharma, Alentis Therapeutics, RayzeBio and Camp4 Therapeutics are ramping up on series funds.
The last few weeks have seen a flurry of filings for initial public offerings by biotech companies. Here’s a look.
PRESS RELEASES